QualityStocks would like to highlight A.P. Pharma, Inc. (OTCBB: APPA), a specialty pharmaceutical company developing products using its proprietary Biochronomer™ polymer-based drug delivery technology. The company’s primary focus is on its lead product, APF530, for the prevention of CINV. A.P. Pharma received a Complete Response Letter on the APF530 NDA and is targeting the resubmission of the NDA in mid-2012.
In the company’s news yesterday,
A.P. Pharma announced that the U.S. Patent and Trademark Office (USPTO) has allowed three new patents covering APF530, the company’s lead product candidate for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV).
A.P. Pharma president and CEO John B. Whelan called the patents “instrumental” in augmenting the product’s overall patent life, which will extend through 2024.
“A.P. Pharma continues to make advancements related to APF530 beyond clinical and regulatory development, and the allowance of these patents provides added strength to the APF530 patent estate and will help support the product’s longevity,” Whelan stated in the press release.
The company offered the following details on patent coverage:
• U.S. Patent application number 13/279,949, entitled “Process for Preparing a Semi-Solid Delivery Vehicle Comprising Granisetron,” relates to methods for preparing extended release formulations of granisetron.
• U.S. Patent application number 13/279,938, entitled “Methods of Treating Emesis Utilizing Semi-Solid Pharmaceutical Compositions Comprising Granisetron,” relates to methods for the treatment of emesis using extended release formulations of granisetron.
• U.S. Patent application number 12/564,881, entitled “Semi-Solid Delivery Vehicle and Pharmaceutical Compositions for Delivery of Granisetron,” relates to compositions for extended delivery of granisetron.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
